Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | FASN | P49327 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5021846 | 0.82 | USP2 (0.44) | USP2MTNR1AMTNR1BL3MBTL1EPHX1 | |
| SCHEMBL12265151 | 0.79 | PSEN1 (0.46) | EPHX1ALDH1A1SMN1; SMN2 | |
| SCHEMBL10224264 | 0.79 | PSEN1 (0.46) | EPHX1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2450442 | 0.79 | CYP3A4 (0.38) | USP2ALDH1A1KMT2AHPGD | |
| SCHEMBL2452522 | 0.79 | CYP3A4 (0.35) | USP2ALDH1A1KMT2AHPGD | |
| SCHEMBL18361602 | 0.76 | TRPV1 (0.41) | USP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL29315229 | 0.76 | PSEN1 (0.42) | USP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL20713172 | 0.76 | USP2 (0.60) | USP2EPHX1ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL10272557 | 0.76 | USP2 (0.60) | USP2EPHX1ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL24475211 | 0.74 | PSEN1 (0.41) | USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148367-B2 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20100105665-A1 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105665-A1 | RENIN INHIBITORS | REN, ACE, AGT | USP2 2836/4885MTNR1A 2274/4885MTNR1B 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.